Loading…
The European Commission opened an in-depth investigation into Johnson & Johnson's planned $400 million acquisition of a surgical patch from Takeda Pharmaceuticals, citing competition concerns.
Takeda Pharmaceuticals announced it will invest more than 100 million euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany. Initial construction will start immediately, and the facility should be ready for production in 2019.
| Site | Largest | Latest |
|---|---|---|
| Singen, Germany | $106.0M | 2016-11-30 |